#1 Clinical Trials Search in Europe

AMG 732

Clinical trials are investigating AMG 732 in healthy subjects and in people with thyroid eye disease. These studies aim to assess how well the treatment works and to gather safety and other research data. The main focus is on a Phase 1/2 study in an adult population with thyroid eye disease.

Table of contents

Trial overview

The listed study is an interventional study, which means researchers give a study treatment and then measure the results.[1] It is testing AMG 732 in both healthy subjects and people with thyroid eye disease.[1]

The trial title says it is a Phase 1/2 study, so it is part of early clinical research.[1] The brief summary says the study is designed to investigate the efficacy of AMG 732 in subjects with TED after multiple subcutaneous doses.[1]

Who is being studied

The study includes healthy subjects and subjects with thyroid eye disease.[1] Healthy subjects are included so researchers can compare results with people who have the disease.[1]

Thyroid eye disease, also called TED, is the main condition being studied in this trial.[1] The source data do not list more detailed entry rules, so the full participation criteria are not available here.[1]

Study design and phase

This study is in Phase 1/2, which usually means the research is still early and is looking at both safety and possible benefit.[1] The study type is listed as interventional, and the treatment is given by subcutaneous use, which means under the skin.[1]

The intervention list also includes a placebo for AMG 732, described as site-sourced normal saline in sterile single-use vials or ampoules.[1] A placebo is a comparison treatment that does not contain the active study drug.[1]

What the study is measuring

The main outcome is the change from baseline at week 9999 in proptosis measurement in the study eye.[1] Proptosis means how far the eye sticks out, and this is measured with an exophthalmometer, a tool used for this purpose.[1]

Baseline means the starting measurement before treatment begins.[1] By comparing later measurements with the starting point, researchers can see whether the eye bulging changes over time.[1]

Trial status and size

The trial status is listed as Authorised, which means the study has been approved to move forward.[1] The planned enrollment is 40 people, so this is a small early-stage study.[1]

Because the enrollment is limited, the study is likely meant to give an early look at how AMG 732 performs in this patient group.[1] The source data do not provide final results, so the article focuses on the study design and planned measurements rather than outcomes.[1]

What these trial terms mean for patients

If you read this study information, the most important point is that AMG 732 is being tested in people with thyroid eye disease and in healthy subjects.[1] The researchers are looking at whether the treatment changes eye bulging, which is one of the key signs of TED.[1]

The trial uses a placebo comparison, so some participants may receive a look-alike treatment instead of AMG 732.[1] This helps researchers make a fair comparison when they study the results.[1]

In simple terms, this is an early study to learn more about AMG 732 in TED, using careful measurements of the eye and comparing changes over time.[1]

Trial ID Phase Condition studied Status Enrollment
NCT06401044 Phase 1/2 Thyroid Eye Disease Authorised 40

FAQ

  • What is being studied in the AMG 732 clinical trials? The trial is studying AMG 732 in healthy subjects and in people with thyroid eye disease. It is designed to look at the treatment’s effects after multiple subcutaneous doses.
  • Who can take part in the study? The study includes healthy subjects and subjects with thyroid eye disease. The exact entry rules are set by the trial team.
  • What phase is the AMG 732 trial? This is a Phase 1/2 study. Phase 1/2 trials usually look at early safety and also begin to explore whether the treatment may help.
  • What condition is the trial focused on? The main condition studied is thyroid eye disease, also called TED. This disease affects the eyes and is the main target of the study.
  • What result is the study measuring? The main result is the change in proptosis measurement in the study eye. Proptosis means how far the eye sticks out, and it is measured with an exophthalmometer.

Ongoing Clinical Trials on AMG 732

  • AMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

    Recruiting

    2 1 1
    Investigated drugs:
    Poland Spain

  • Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

    Recruiting

    2 1
    Investigated drugs:
    France Germany Greece Italy Poland Spain

Glossary

  • Thyroid Eye Disease (TED): A disease that affects the eyes and can make them bulge or feel uncomfortable. It is the main condition being studied in this trial.
  • Healthy subjects: People who do not have the study disease and are included to help researchers compare results.
  • Phase 1/2: An early stage of clinical research. It usually looks at safety first and also starts to check whether the treatment may work.
  • Interventional study: A study where researchers give a treatment or placebo and then measure what happens.
  • Placebo: A look-alike treatment with no active study drug. It helps researchers compare results fairly.
  • Subcutaneous use: Given under the skin, usually by injection.
  • Proptosis: Forward bulging of the eye. This trial measures how much it changes over time.
  • Exophthalmometer: A tool used to measure how far the eye sticks out.
  • Baseline: The starting point before treatment begins. Later measurements are compared with this starting value.
  • Enrollment: The number of people planned or included in the study.

References